Table 3 Crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for prognostic factors associated with the risk of breast cancer death

From: Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women

 

Crude HR

Adjusted HR (CR) a

Adjusted HR (CR) b

   

P -value

  

P -value

  

P -value

Age at first onset (years)

     

0.1927

   

 <35

1.23

(0.93−1.62)

0.15

1.20

(0.78−1.84)

    

 35−44

0.94

(0.77−1.13)

0.50

0.81

(0.60−1.09)

    

 ⩾45

1.00

—

 

1.00

—

    

Type

         

 Unilateral

1.00

—

 

1.00

—

 

1.00

—

 

 Bilateral

3.27

(2.15−4.97)

<0.0001

3.04

(1.97−4.69)

<0.0001

2.50

(1.43−4.37)

0.001

Type 2

     

0.0002

  

<0.0001

 Unilateral

1.00

—

 

1.00

—

 

1.00

—

 

 Synchronous

1.52

(0.68−3.40)

0.31

2.91

(0.40−21.46)

 

1.12

(0.42−3.02)

 

 Metachronous

5.68

(3.45−9.37)

<0.0001

8.35

(2.99−23.32)

 

6.11

(3.14−11.89)

 

Histology type

     

0.0013

  

0.0206

 IDC

0.98

(0.73−1.30)

0.88

1.00

(0.74−1.35)

 

0.92

(0.69−1.24)

 

 DCIS

0.23

(0.12−0.47)

0.23

0.27

(0.13−0.54)

 

0.34

(0.17−0.69)

 

 ILC

1.30

(0.68−2.49)

0.43

1.16

(0.60−2.23)

 

1.15

(0.60−2.22)

 

 Others

1.00

—

 

1.00

—

 

1.00

—

 

Oestrogen receptor

 −

1.00

—

 

1.00

—

    

 +

0.74

(0.61−0.91)

0.004

0.80

(0.59−1.08)

0.15

   

Progesterone receptor

 −

1.00

—

 

1.00

—

    

 +

0.78

(0.64−0.96)

0.02

0.77

(0.57−1.03)

0.08

   

Chemotherapy

         

 −

1.00

—

 

1.00

—

    

 +

3.36

(2.70−4.20)

<0.0001

1.40

(0.98−1.98)

0.06

   

Radiotherapy

         

 −

1.00

—

 

1.00

—

    

 +

1.49

(1.14−1.95)

0.004

1.11

(0.73−1.70)

0.62

   

Tamoxifen

         

 −

1.00

—

 

1.00

—

    

 +

1.28

(1.00−1.63)

0.047

1.33

(0.93−1.89)

0.12

   

Axillary lymph node metastasis

 −

1.00

—

 

1.00

—

 

1.00

—

 

 +

4.10

(3.24−5.18)

<0.0001

2.56

(1.84−3.56)

<0.0001

3.43

(2.67−4.42)

<0.0001

Size (cm)

         

 <2

1.00

—

 

1.00

—

 

1.00

—

 

 ⩾2

2.50

(1.84−3.38)

<0.0001

1.59

(1.06−2.39)

0.02

1.85

(1.30−2.62)

0.0006

Family history

         

 −

1.00

—

 

1.00

—

 

1.00

—

 

 +

1.44

(1.02−2.03)

0.04

1.42

(1.01−2.01)

0.04

1.49

(1.06−2.11)

0.02

  1. DCIS=ductal carcinoma in situ; IDC=infiltrating ductal carcinoma; ILC=infiltrating lobular carcinoma.
  2. aControlling for all variables.
  3. bControlling for significant variables in multivariate analysis, including type of breast cancer, histology type of breast cancer, tumour size, regional lymph node involvement, and family history when overall bilateral breast cancer was compared with unilateral breast cancer; chemotherapy was also considered when metachronous and synchronous breast cancer were compared with unilateral breast cancer. Note that the adjusted HRs for the controlling variables provided in Table 3 were based on the model comparing overall bilateral breast cancer and unilateral breast cancer.
Back to article page